DUBLIN & NORWALK, Conn. -- -- Inflection Biosciences Ltd., a private company developing highly innovative treatments for cancer, today announced a collaboration with the Multiple Myeloma Research Foundation on pre-clinical testing of its innovative dual mechanism PIM/PI3K inhibitor IBL-202.
via Norwalk Newswire http://www.freshnews.com/news/1042881/multiple-myeloma-research-foundation-and-inflection-biosciences-collaborate-new-cancer
via Norwalk Newswire http://www.freshnews.com/news/1042881/multiple-myeloma-research-foundation-and-inflection-biosciences-collaborate-new-cancer
No comments:
Post a Comment